Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Non-Current Assets (2021 - 2026)

Indivior Pharmaceuticals has reported Non-Current Assets over the past 6 years, most recently at $530.0 million for Q1 2026.

  • For Q1 2026, Non-Current Assets rose 7.72% year-over-year to $530.0 million; the TTM value through Mar 2026 reached $2.1 billion, changed N/A, while the annual FY2025 figure was $549.0 million, 12.27% up from the prior year.
  • Non-Current Assets for Q1 2026 was $530.0 million at Indivior Pharmaceuticals, down from $549.0 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $691.0 million in Q4 2023 and troughed at $489.0 million in Q4 2024.
  • A 5-year average of $532.0 million and a median of $505.5 million in 2022 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: surged 35.49% in 2023 and later decreased 29.23% in 2024.
  • Year by year, Non-Current Assets stood at $510.0 million in 2022, then skyrocketed by 35.49% to $691.0 million in 2023, then fell by 29.23% to $489.0 million in 2024, then increased by 12.27% to $549.0 million in 2025, then fell by 3.46% to $530.0 million in 2026.
  • Business Quant data shows Non-Current Assets for INDV at $530.0 million in Q1 2026, $549.0 million in Q4 2025, and $494.0 million in Q3 2025.